Skip to content
Back to TRDA

Entrada Therapeutics, Inc.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 18, 2025
Transactions
47
Purchases
5
Sales
42
Purchase value
$291.16K
Sale value
$6.74M

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

MPM BioVentures 2018 GP LLC10% owner
MPM BioVentures 2018 LLC10% owner
MPM Bioventures 2018, L.P.10% owner
4
Filed Sep 9, 2026Period of report Sep 4, 20260001231919-26-001156
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 9, 2026
Common StockF8F9F4F1028,837$7.13$205.61K3,885,115IndirectSee Footnote
SaleSep 8, 2026
Common StockF5F6F4F7192,500$7.41$1.43M3,913,952IndirectSee Footnote
SaleSep 4, 2026
Common StockF1F2F3F438,500$7.11$273.74K4,106,452IndirectSee Footnote
Filing footnotes · 10
  1. F1The shares were sold as follows: 17,482 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,166 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 602 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 17,942 by MPM BioVentures 2018, L.P. ("BV 2018"), 954 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 354 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC.
  2. F10The shares are held as follows: 1,764,167 by BV 2014, 117,667 by BV 2014(B), 60,722 by AM BV2014, 1,810,592 by BV 2018, 96,232 by BV 2018(B) and 35,735 by AM BV2018.
  3. F2Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.01 to $7.16 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  4. F3The shares are held as follows: 1,864,673 by BV 2014, 124,370 by BV 2014(B), 64,182 by AM BV2014, 1,913,743 by BV 2018, 101,714 by BV 2018(B) and 37,770 by AM BV2018.
  5. F4Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
  6. F5The shares were sold as follows: 87,411 by BV 2014, 5,830 by BV 2014(B), 3,009 by AM BV2014, 89,712 by BV 2018, 4,768 by BV 2018(B) and 1,770 by AM BV2018.
  7. F6Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  8. F7The shares are held as follows: 1,777,262 by BV 2014, 118,540 by BV 2014(B), 61,173 by AM BV2014, 1,824,031 by BV 2018, 96,946 by BV 2018(B) and 36,000 by AM BV2018.
  9. F8The shares were sold as follows: 13,095 by BV 2014, 873 by BV 2014(B), 451 by AM BV2014, 13,439 by BV 2018, 714 by BV 2018(B) and 265 by AM BV2018.
  10. F9Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.02 to $7.54 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Open on SEC EDGAR
Evnin Luke10% owner
Foley Todd10% owner
Gadicke Ansbert10% owner
MPM Asset Management Investors BV2014 LLC10% owner
MPM Asset Management Investors BV2018 LLC10% owner
MPM BioVentures 2014 (B), L.P.10% owner
MPM BioVentures 2014 GP LLC10% owner
MPM BioVentures 2014 LLC10% owner
MPM BioVentures 2014, L.P.10% owner
MPM Bioventures 2018 (B), L.P.10% owner
4
Filed Sep 9, 2026Period of report Sep 4, 20260001231919-26-001155
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 9, 2026
Common StockF8F9F4F1028,837$7.13$205.61K3,885,115IndirectSee Footnote
SaleSep 8, 2026
Common StockF5F6F4F7192,500$7.41$1.43M3,913,952IndirectSee Footnote
SaleSep 4, 2026
Common StockF1F2F3F438,500$7.11$273.74K4,106,452IndirectSee Footnote
Filing footnotes · 10
  1. F1The shares were sold as follows: 17,482 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,166 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 602 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 17,942 by MPM BioVentures 2018, L.P. ("BV 2018"), 954 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 354 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC.
  2. F10The shares are held as follows: 1,764,167 by BV 2014, 117,667 by BV 2014(B), 60,722 by AM BV2014, 1,810,592 by BV 2018, 96,232 by BV 2018(B) and 35,735 by AM BV2018.
  3. F2Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.01 to $7.16 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  4. F3The shares are held as follows: 1,864,673 by BV 2014, 124,370 by BV 2014(B), 64,182 by AM BV2014, 1,913,743 by BV 2018, 101,714 by BV 2018(B) and 37,770 by AM BV2018.
  5. F4Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
  6. F5The shares were sold as follows: 87,411 by BV 2014, 5,830 by BV 2014(B), 3,009 by AM BV2014, 89,712 by BV 2018, 4,768 by BV 2018(B) and 1,770 by AM BV2018.
  7. F6Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  8. F7The shares are held as follows: 1,777,262 by BV 2014, 118,540 by BV 2014(B), 61,173 by AM BV2014, 1,824,031 by BV 2018, 96,946 by BV 2018(B) and 36,000 by AM BV2018.
  9. F8The shares were sold as follows: 13,095 by BV 2014, 873 by BV 2014(B), 451 by AM BV2014, 13,439 by BV 2018, 714 by BV 2018(B) and 265 by AM BV2018.
  10. F9Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.02 to $7.54 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Open on SEC EDGAR
MPM BioVentures 2018 GP LLC10% owner
MPM BioVentures 2018 LLC10% owner
MPM Bioventures 2018, L.P.10% owner
4
Filed Sep 3, 2026Period of report Sep 1, 20260001231919-26-001144
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 3, 2026
Common StockF8F9F4F1032,263$7.17$231.33K4,144,952IndirectSee Footnote
SaleSep 2, 2026
Common StockF5F6F4F725,131$7.19$180.69K4,177,215IndirectSee Footnote
SaleSep 1, 2026
Common StockF1F2F3F429,088$7.06$205.36K4,202,346IndirectSee Footnote
Filing footnotes · 10
  1. F1The shares were sold as follows: 13,208 by MPM BioVentures 2014, L.P. ("BV 2014"), 881 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 455 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 13,556 by MPM BioVentures 2018, L.P. ("BV 2018"), 720 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 268 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC.
  2. F10The shares are held as follows: 1,882,155 by BV 2014, 125,536 by BV 2014(B), 64,784 by AM BV2014, 1,931,685 by BV 2018, 102,668 by BV 2018(B) and 38,124 by AM BV2018.
  3. F2Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.80 to $7.15 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  4. F3The shares are held as follows: 1,908,217 by BV 2014, 127,274 by BV 2014(B), 65,681 by AM BV2014, 1,958,433 by BV 2018, 104,089 by BV 2018(B) and 38,652 by AM BV2018.
  5. F4Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
  6. F5The shares were sold as follows: 11,412 by BV 2014, 761 by BV 2014(B), 393 by AM BV2014, 11,712 by BV 2018, 622 by BV 2018(B) and 231 by AM BV2018.
  7. F6Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.9601 to $7.3273 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  8. F7The shares are held as follows: 1,896,805 by BV 2014, 126,513 by BV 2014(B), 65,288 by AM BV2014, 1,946,721 by BV 2018, 103,467 by BV 2018(B) and 38,421 by AM BV2018.
  9. F8The shares were sold as follows: 14,650 by BV 2014, 977 by BV 2014(B), 504 by AM BV2014, 15,036 by BV 2018, 799 by BV 2018(B) and 297 by AM BV2018.
  10. F9Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.0434 to $7.405 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Open on SEC EDGAR
Evnin Luke10% owner
Foley Todd10% owner
Gadicke Ansbert10% owner
MPM Asset Management Investors BV2014 LLC10% owner
MPM Asset Management Investors BV2018 LLC10% owner
MPM BioVentures 2014 (B), L.P.10% owner
MPM BioVentures 2014 GP LLC10% owner
MPM BioVentures 2014 LLC10% owner
MPM BioVentures 2014, L.P.10% owner
MPM Bioventures 2018 (B), L.P.10% owner
4
Filed Sep 3, 2026Period of report Sep 1, 20260001231919-26-001143
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 3, 2026
Common StockF8F9F4F1032,263$7.17$231.33K4,144,952IndirectSee Footnote
SaleSep 2, 2026
Common StockF5F6F4F725,131$7.19$180.69K4,177,215IndirectSee Footnote
SaleSep 1, 2026
Common StockF1F2F3F429,088$7.06$205.36K4,202,346IndirectSee Footnote
Filing footnotes · 10
  1. F1The shares were sold as follows: 13,208 by MPM BioVentures 2014, L.P. ("BV 2014"), 881 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 455 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 13,556 by MPM BioVentures 2018, L.P. ("BV 2018"), 720 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 268 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC.
  2. F10The shares are held as follows: 1,882,155 by BV 2014, 125,536 by BV 2014(B), 64,784 by AM BV2014, 1,931,685 by BV 2018, 102,668 by BV 2018(B) and 38,124 by AM BV2018.
  3. F2Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.80 to $7.15 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  4. F3The shares are held as follows: 1,908,217 by BV 2014, 127,274 by BV 2014(B), 65,681 by AM BV2014, 1,958,433 by BV 2018, 104,089 by BV 2018(B) and 38,652 by AM BV2018.
  5. F4Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
  6. F5The shares were sold as follows: 11,412 by BV 2014, 761 by BV 2014(B), 393 by AM BV2014, 11,712 by BV 2018, 622 by BV 2018(B) and 231 by AM BV2018.
  7. F6Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.9601 to $7.3273 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  8. F7The shares are held as follows: 1,896,805 by BV 2014, 126,513 by BV 2014(B), 65,288 by AM BV2014, 1,946,721 by BV 2018, 103,467 by BV 2018(B) and 38,421 by AM BV2018.
  9. F8The shares were sold as follows: 14,650 by BV 2014, 977 by BV 2014(B), 504 by AM BV2014, 15,036 by BV 2018, 799 by BV 2018(B) and 297 by AM BV2018.
  10. F9Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.0434 to $7.405 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Open on SEC EDGAR
MPM BioVentures 2018 GP LLC10% owner
MPM BioVentures 2018 LLC10% owner
MPM Bioventures 2018, L.P.10% owner
4
Filed Aug 31, 2026Period of report Aug 27, 20260001231919-26-001136
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 31, 2026
Common StockF8F9F4F1044,259$6.99$309.37K4,231,434IndirectSee Footnote
SaleAug 28, 2026
Common StockF5F6F4F73,733$7.01$26.17K4,275,693IndirectSee Footnote
SaleAug 27, 2026
Common StockF1F2F3F438,922$7.20$280.24K4,279,426IndirectSee Footnote
Filing footnotes · 10
  1. F1The shares were sold as follows: 17,674 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,179 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 608 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 18,139 by MPM BioVentures 2018, L.P. ("BV 2018"), 964 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 358 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC.
  2. F10The shares are held as follows: 1,921,425 by BV 2014, 128,155 by BV 2014(B), 66,136 by AM BV2014, 1,971,989 by BV 2018, 104,809 by BV 2018(B) and 38,920 by AM BV2018.
  3. F2Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.88 to $7.37 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  4. F3The shares are held as follows: 1,943,217 by BV 2014, 129,609 by BV 2014(B), 66,886 by AM BV2014, 1,994,355 by BV 2018, 105,998 by BV 2018(B) and 39,361 by AM BV2018.
  5. F4Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
  6. F5The shares were sold as follows: 1,695 by BV 2014, 113 by BV 2014(B), 58 by AM BV2014, 1,740 by BV 2018, 93 by BV 2018(B) and 34 by AM BV2018.
  7. F6Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.95 to $7.24 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  8. F7The shares are held as follows: 1,941,522 by BV 2014, 129,496 by BV 2014(B), 66,828 by AM BV2014, 1,992,615 by BV 2018, 105,905 by BV 2018(B) and 39,327 by AM BV2018.
  9. F8The shares were sold as follows: 20,097 by BV 2014, 1,341 by BV 2014(B), 692 by AM BV2014, 20,626 by BV 2018, 1,096 by BV 2018(B) and 407 by AM BV2018.
  10. F9Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.76 to $7.1626 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Open on SEC EDGAR
Evnin Luke10% owner
Foley Todd10% owner
Gadicke Ansbert10% owner
MPM Asset Management Investors BV2014 LLC10% owner
MPM Asset Management Investors BV2018 LLC10% owner
MPM BioVentures 2014 (B), L.P.10% owner
MPM BioVentures 2014 GP LLC10% owner
MPM BioVentures 2014 LLC10% owner
MPM BioVentures 2014, L.P.10% owner
MPM Bioventures 2018 (B), L.P.10% owner
4
Filed Aug 31, 2026Period of report Aug 27, 20260001231919-26-001135
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 31, 2026
Common StockF8F9F4F1044,259$6.99$309.37K4,231,434IndirectSee Footnote
SaleAug 28, 2026
Common StockF5F6F4F73,733$7.01$26.17K4,275,693IndirectSee Footnote
SaleAug 27, 2026
Common StockF1F2F3F438,922$7.20$280.24K4,279,426IndirectSee Footnote
Filing footnotes · 10
  1. F1The shares were sold as follows: 17,674 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,179 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 608 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 18,139 by MPM BioVentures 2018, L.P. ("BV 2018"), 964 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 358 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC.
  2. F10The shares are held as follows: 1,921,425 by BV 2014, 128,155 by BV 2014(B), 66,136 by AM BV2014, 1,971,989 by BV 2018, 104,809 by BV 2018(B) and 38,920 by AM BV2018.
  3. F2Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.88 to $7.37 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  4. F3The shares are held as follows: 1,943,217 by BV 2014, 129,609 by BV 2014(B), 66,886 by AM BV2014, 1,994,355 by BV 2018, 105,998 by BV 2018(B) and 39,361 by AM BV2018.
  5. F4Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
  6. F5The shares were sold as follows: 1,695 by BV 2014, 113 by BV 2014(B), 58 by AM BV2014, 1,740 by BV 2018, 93 by BV 2018(B) and 34 by AM BV2018.
  7. F6Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.95 to $7.24 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  8. F7The shares are held as follows: 1,941,522 by BV 2014, 129,496 by BV 2014(B), 66,828 by AM BV2014, 1,992,615 by BV 2018, 105,905 by BV 2018(B) and 39,327 by AM BV2018.
  9. F8The shares were sold as follows: 20,097 by BV 2014, 1,341 by BV 2014(B), 692 by AM BV2014, 20,626 by BV 2018, 1,096 by BV 2018(B) and 407 by AM BV2018.
  10. F9Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.76 to $7.1626 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Open on SEC EDGAR
Evnin Luke10% owner
Foley Todd10% owner
Gadicke Ansbert10% owner
MPM Asset Management Investors BV2014 LLC10% owner
MPM Asset Management Investors BV2018 LLC10% owner
MPM BioVentures 2014 (B), L.P.10% owner
MPM BioVentures 2014 GP LLC10% owner
MPM BioVentures 2014 LLC10% owner
MPM BioVentures 2014, L.P.10% owner
MPM Bioventures 2018 (B), L.P.10% owner
4
Filed Aug 26, 2026Period of report Aug 24, 20260001231919-26-001107
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 26, 2026
Common StockF8F9F4F1014,569$7.06$102.86K4,318,348IndirectSee Footnote
SaleAug 25, 2026
Common StockF5F6F4F726,522$7.54$199.98K4,332,917IndirectSee Footnote
SaleAug 24, 2026
Common StockF1F2F3F421,623$7.34$158.71K4,359,439IndirectSee Footnote
Filing footnotes · 10
  1. F1The shares were sold as follows: 9,819 by MPM BioVentures 2014, L.P. ("BV 2014"), 655 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 338 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 10,077 by MPM BioVentures 2018, L.P. ("BV 2018"), 535 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 199 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC.
  2. F10The shares are held as follows: 1,960,891 by BV 2014, 130,788 by BV 2014(B), 67,494 by AM BV2014, 2,012,494 by BV 2018, 106,962 by BV 2018(B) and 39,719 by AM BV2018.
  3. F2Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.0852 to $7.58 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  4. F3The shares are held as follows: 1,979,549 by BV 2014, 132,032 by BV 2014(B), 68,137 by AM BV2014, 2,031,644 by BV 2018, 107,980 by BV 2018(B) and 40,097 by AM BV2018.
  5. F4Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
  6. F5The shares were sold as follows: 12,043 by BV 2014, 803 by BV 2014(B), 415 by AM BV2014, 12,360 by BV 2018, 657 by BV 2018(B) and 244 by AM BV2018.
  7. F6Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.28 to $7.6421 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  8. F7The shares are held as follows: 1,967,506 by BV 2014, 131,229 by BV 2014(B), 67,722 by AM BV2014, 2,019,284 by BV 2018, 107,323 by BV 2018(B) and 39,853 by AM BV2018.
  9. F8The shares were sold as follows: 6,615 by BV 2014, 441 by BV 2014(B), 228 by AM BV2014, 6,790 by BV 2018, 361 by BV 2018(B) and 134 by AM BV2018.
  10. F9Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.55 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Open on SEC EDGAR
MPM BioVentures 2018 GP LLC10% owner
MPM BioVentures 2018 LLC10% owner
MPM Bioventures 2018, L.P.10% owner
4
Filed Aug 26, 2026Period of report Aug 24, 20260001231919-26-001106
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 26, 2026
Common StockF8F9F4F1014,569$7.06$102.86K4,318,348IndirectSee Footnote
SaleAug 25, 2026
Common StockF5F6F4F726,522$7.54$199.98K4,332,917IndirectSee Footnote
SaleAug 24, 2026
Common StockF1F2F3F421,623$7.34$158.71K4,359,439IndirectSee Footnote
Filing footnotes · 10
  1. F1The shares were sold as follows: 9,819 by MPM BioVentures 2014, L.P. ("BV 2014"), 655 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 338 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 10,077 by MPM BioVentures 2018, L.P. ("BV 2018"), 535 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 199 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC.
  2. F10The shares are held as follows: 1,960,891 by BV 2014, 130,788 by BV 2014(B), 67,494 by AM BV2014, 2,012,494 by BV 2018, 106,962 by BV 2018(B) and 39,719 by AM BV2018.
  3. F2Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.0852 to $7.58 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  4. F3The shares are held as follows: 1,979,549 by BV 2014, 132,032 by BV 2014(B), 68,137 by AM BV2014, 2,031,644 by BV 2018, 107,980 by BV 2018(B) and 40,097 by AM BV2018.
  5. F4Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
  6. F5The shares were sold as follows: 12,043 by BV 2014, 803 by BV 2014(B), 415 by AM BV2014, 12,360 by BV 2018, 657 by BV 2018(B) and 244 by AM BV2018.
  7. F6Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.28 to $7.6421 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  8. F7The shares are held as follows: 1,967,506 by BV 2014, 131,229 by BV 2014(B), 67,722 by AM BV2014, 2,019,284 by BV 2018, 107,323 by BV 2018(B) and 39,853 by AM BV2018.
  9. F8The shares were sold as follows: 6,615 by BV 2014, 441 by BV 2014(B), 228 by AM BV2014, 6,790 by BV 2018, 361 by BV 2018(B) and 134 by AM BV2018.
  10. F9Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.55 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Open on SEC EDGAR
Kush ParmarDirector
4
Filed Aug 10, 2026Period of report Aug 6, 20260001664281-26-000004
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 10, 2026
Common StockF4F292,444$7.00$647.11K2,691,337IndirectBy 5AM Ventures V, L.P.
SaleAug 7, 2026
Common StockF352,317$6.85$358.37K2,783,781IndirectBy 5AM Ventures V, L.P.
SaleAug 6, 2026
Common StockF1F210,494$7.00$73.46K2,836,098IndirectBy 5AM Ventures V, L.P.
Filing footnotes · 5
  1. F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.90 to $7.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  2. F2Shares are held by 5AM Ventures V, L.P. ("5AM V"). 5AM Partners V, LLC ("5AM Partners") is the sole general partner of 5AM V. Kush M. Parmar, M.D., Ph.D. is a managing member of 5AM Partners and may be deemed to share voting and investment power over the shares held by 5AM V. Dr. Parmar disclaims beneficial ownership of the shares held by 5AM V except to the extent of his pecuniary interest therein.
  3. F3The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $6.80 to $7.01 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
  4. F4The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $6.84 to $7.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
  5. F5Shares are held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Kush M. Parmar, M.D., Ph.D. is a managing member of Opportunities GP and may be deemed to share voting and investment power over the shares held by Opportunities. Dr. Parmar disclaims beneficial ownership of the shares held by Opportunities except to the extent of his pecuniary interest therein.
Open on SEC EDGAR
5AM Opportunities I (GP), LLC10% owner
5AM Opportunities I, L.P.10% owner
5AM Partners V, LLC10% owner
5AM Ventures V, L.P.10% owner
Rocklage Scott M10% owner
Schwab Andrew J.10% owner
4
Filed Aug 10, 2026Period of report Aug 6, 20260001231919-26-000854
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 7, 2026
Common StockF3F252,317$6.85$358.37K2,783,781Direct
SaleAug 6, 2026
Common StockF1F210,494$7.00$73.46K2,836,098Direct
Filing footnotes · 4
  1. F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.90 to $7.11 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  2. F2Shares are held by 5AM Ventures V, L.P. ("5AM V"). 5AM Partners V, LLC ("5AM Partners") is the sole general partner of 5AM V. Dr. Kush Parmar, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners and may be deemed to have shared voting and investment power over the shares beneficially owned by 5AM V. Each of 5AM Partners, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock held by 5AM V, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports.
  3. F3The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $6.80 to $7.01 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
  4. F4Shares are held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held by Opportunities, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports.
Open on SEC EDGAR
Kush ParmarDirector · 10% owner
4
Filed Aug 3, 2026Period of report Jul 30, 20260001664281-26-000002
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 31, 2026
Common Stock1,718$6.85$11.77K2,846,592IndirectBy 5AM Ventures V, L.P.
SaleJul 30, 2026
Common StockF1F2114,756$6.93$795.26K2,848,310IndirectBy 5AM Ventures V, L.P.
Filing footnotes · 3
  1. F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.75 to $6.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  2. F2Shares are held by 5AM Ventures V, L.P. ("5AM V"). 5AM Partners V, LLC ("5AM Partners") is the sole general partner of 5AM V. Kush M. Parmar, M.D., Ph.D. is a managing member of 5AM Partners and may be deemed to share voting and investment power over the shares held by 5AM V. Dr. Parmar disclaims beneficial ownership of the shares held by 5AM V except to the extent of his pecuniary interest therein.
  3. F3Shares are held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Kush M. Parmar, M.D., Ph.D. is a managing member of Opportunities GP and may be deemed to share voting and investment power over the shares held by Opportunities. Dr. Parmar disclaims beneficial ownership of the shares held by Opportunities except to the extent of his pecuniary interest therein.
Open on SEC EDGAR
5AM Opportunities I (GP), LLC10% owner
5AM Opportunities I, L.P.10% owner
5AM Partners V, LLC10% owner
5AM Ventures V, L.P.10% owner
Rocklage Scott M10% owner
Schwab Andrew J.10% owner
4
Filed Aug 3, 2026Period of report Jul 30, 20260001231919-26-000822
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 31, 2026
Common StockF21,718$6.85$11.77K2,846,592Direct
SaleJul 30, 2026
Common StockF1F2114,756$6.93$795.26K2,848,310Direct
Filing footnotes · 3
  1. F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.75 to $6.95 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  2. F2Shares are held by 5AM Ventures V, L.P. ("5AM V"). 5AM Partners V, LLC ("5AM Partners") is the sole general partner of 5AM V. Dr. Kush Parmar, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners and may be deemed to have shared voting and investment power over the shares beneficially owned by 5AM V. Each of 5AM Partners, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock held by 5AM V, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports.
  3. F3Shares are held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held by Opportunities, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports.
Open on SEC EDGAR
Bernhardt G ZeiherDirector
4
Filed May 21, 2026Period of report May 20, 20260001689375-26-000030
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseMay 20, 2026
Common StockF1F25,000$5.8632$29.32K5,000IndirectBy Bernhardt G Zeiher and Paula B Zeiher Revocable Living Trust Agreement
Filing footnotes · 2
  1. F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.86 to $6.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  2. F2The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
Open on SEC EDGAR
Natarajan SethuramanPresident, Research & Develop.
4Rule 10b5-1 plan disclosed
Filed May 4, 2026Period of report May 4, 20260001873394-26-000003
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 4, 2026
Common StockF1F225,907$15.3939$398.81K216,317Direct
Filing footnotes · 2
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2024.
  2. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.6150, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open on SEC EDGAR
Nathan J DowdenPresident & COO
4Rule 10b5-1 plan disclosed
Filed May 4, 2026Period of report May 4, 20260001873392-26-000004
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 4, 2026
Common StockF1F215,000$15.3302$229.95K198,588Direct
Filing footnotes · 3
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2025.
  2. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3The shares subject to this option fully vested on November 4, 2023.
Open on SEC EDGAR
Kory James WentworthChief Financial Officer
4Rule 10b5-1 plan disclosed
Filed Apr 2, 2026Period of report Apr 1, 20260001725663-26-000005
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 1, 2026
Common StockF12,500$12.95$32.38K119,010Direct
Filing footnotes · 1
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2025.
Open on SEC EDGAR
Nathan J DowdenPresident & COO
4Rule 10b5-1 plan disclosed
Filed Mar 11, 2026Period of report Mar 9, 20260001873392-26-000002
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 10, 2026
Common StockF1F311,894$13.0476$155.19K198,588Direct
SaleMar 9, 2026
Common StockF1F23,116$13.024$40.58K210,482Direct
Filing footnotes · 3
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2025.
  2. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open on SEC EDGAR
Kory James WentworthChief Financial Officer
4Rule 10b5-1 plan disclosed
Filed Mar 11, 2026Period of report Mar 9, 20260001725663-26-000003
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 10, 2026
Common StockF1F311,388$13.0151$148.22K121,510Direct
SaleMar 9, 2026
Common StockF1F25,089$13.0011$66.16K132,898Direct
Filing footnotes · 3
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2025.
  2. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.95 to $13.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.95 to $13.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open on SEC EDGAR
Kory James WentworthChief Financial Officer
4Rule 10b5-1 plan disclosed
Filed Mar 6, 2026Period of report Mar 4, 20260001725663-26-000002
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 4, 2026
Common StockF1F27,988$12.2549$97.89K137,987Direct
Filing footnotes · 2
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2025.
  2. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.80 to $12.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open on SEC EDGAR
Kory James WentworthChief Financial Officer
4Rule 10b5-1 plan disclosed
Filed Nov 24, 2025Period of report Nov 21, 20250001725663-25-000004
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 21, 2025
Common StockF1F28,910$9.9811$88.93K110,026Direct
Filing footnotes · 2
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2025.
  2. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.95 to $10.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open on SEC EDGAR
Baker Bros. Advisors (GP) LLC10% owner
Baker Bros. Advisors LP10% owner
Baker Felix10% owner
Baker Julian10% owner
4
Filed Nov 24, 2025Period of report Nov 20, 20250001193125-25-293698
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseNov 20, 2025
Common StockF1F2F3F41,213$9.0688$11.00K380,152IndirectSee Footnotes
PurchaseNov 20, 2025
Common StockF1F3F4F513,386$9.0688$121.39K4,678,310IndirectSee Footnotes
PurchaseNov 20, 2025
Common StockF6F2F3F41,186$9.0728$10.76K381,338IndirectSee Footnotes
PurchaseNov 20, 2025
Common StockF6F3F4F513,082$9.0728$118.69K4,691,392IndirectSee Footnotes
Filing footnotes · 6
  1. F1The price reported in Column 4 is a weighted average price. These shares of common stock ("Common Stock") of Entrada Therapeutics, Inc. (the "Issuer") were traded by 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") in multiple transactions at prices ranging from $8.82 to $9.25, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Staff"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  2. F2After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
  3. F3Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.
  4. F4Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
  5. F5After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
  6. F6The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $8.85 to $9.20, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.